secwatch.observer — SEC 8-K summary
======================================

Issuer:     Emergent BioSolutions Inc. (EBS)
CIK:        0001367644
Form:       8-K
Filed at:   2021-07-22T23:59:59+00:00
Accession:  0001367644-21-000110
Event type: leadership
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Emergent BioSolutions expands Adam Havey to EVP and COO effective July 26
-------------------------------------------------------------------------

- Adam Havey appointed Executive Vice President and Chief Operating Officer on July 20, 2021, effective July 26.
- Havey, 50, joined Emergent in 2003 and previously served as EVP Business Operations since April 2017.
- Reorganization of executive team approved by Board; Havey becomes principal operating officer.
- He will oversee expanded responsibilities as part of the CEO's proposed restructuring.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1367644/000136764421000110/0001367644-21-000110-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1367644/000136764421000110/ebs-20210720.htm
  HTML page:      https://secwatch.observer/filing/0001367644-21-000110

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer